PROCESS FOR PREPARING EXTREME PURE BUSPIRON AND HYDROCHLORIDE THEREOF

The invention relates to a process for the preparation of 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione {buspirone} of the formula and of its hydrochlorides by hydrogenating 8-{4'-[4''-(pyrimidin-2'...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BLASKO GABOR DR, NAGY KALMAN DR, REITER KLARA DR, VERECZKEY GYONGYI, BUDAI ZOLTAN DR, CSORGO MARGIT DR, KONCZ LASZLO, SZTRUHAR ILONA DR, SIMIG GYULA DR, MANDI ATTILA DR, SZEGO JUDIT DR, FURDYGA EVA DR, MEZEI LIBOR DR, KLEBOVICH IMRE DR
Format:	Patent
Sprache:	eng
Schlagworte:	APPARATUS THEREFOR CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOIDCHEMISTRY CHEMISTRY GENERAL METHODS OF ORGANIC CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PERFORMING OPERATIONS PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS THEIR RELEVANT APPARATUS TRANSPORTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to a process for the preparation of 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione {buspirone} of the formula and of its hydrochlorides by hydrogenating 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]but-2'-ynyl}-8-azaspiro [4.5 ]decane-7,9-dione of the formula in the presence of a palladium or Raney nickel catalyst in an organic solvent and optionally converting the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione into a hydrochloride, in which a solution of 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]but-2'-ynyl}-8-azaspiro [4.5 ]decane-7,9-dione of the formula II in an organic solvent whose concentration is at least 40% by weight is added to a suspension of the catalyst in an organic solvent, the catalyst is removed and a) the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione base of the formula I is isolated and/or b) the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione base of the formula I is treated with hydrogen chloride at 15 to 40 DEG C in ethanol or isopropanol and the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione hydrochloride melting at 188 to 191 DEG C is isolated or c) the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione base of the formula I is treated at at most 70 DEG C with hydrogen chloride in ethyl acetate or isopropanol and the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]d ecan e-7,9-dione hydrochloride melting at 201 to 203 DEG C is isolated.